Steris Corporation : STERIS Corporation to Announce Fiscal 2013 Third Quarter Financial Results on February 6, 2013

Steris Corporation : STERIS Corporation to Announce Fiscal 2013 Third Quarter
                    Financial Results on February 6, 2013

Mentor, Ohio (January 16, 2013) - STERIS Corporation (NYSE: STE) today
announced that it will release its fiscal 2013 third quarter financial results
before the market opens on February 6, 2013, followed by a conference call at
10:00 a.m. Eastern time. The conference call can be heard live over the
Internet at or via phone by dialing 1- 800-369-8428 in the
United States and Canada, or 1-773-799-3378 internationally, then referencing
the password "STERIS".

For those unable to listen to the conference call live, a replay will be
available beginning at 12:00 p.m. Eastern time on February 6, 2013 either over
the Internet at or via phone by calling 1-800-388-4950 in
the United States and Canada, or 1-203-369-3694 internationally.


The mission of STERIS Corporation is to provide a healthier today and safer
tomorrow through knowledgeable people and innovative infection prevention,
decontamination and health science technologies, products and services. The
Company has approximately 6,000 dedicated employees around the world working
together to supply a broad array of solutions by offering a combination of
equipment, consumables and services to healthcare, pharmaceutical, industrial
and government Customers. The Company is listed on the New York Stock Exchange
under the symbol STE. For more information, visit

                                    # # #

The press release and the referenced conference call may contain statements
concerning certain trends, expectations, forecasts, estimates, or other
forward-looking information affecting or relating to the Company or its
industry, products or activities that are intended to qualify for the
protections afforded "forward-looking statements" under the Private Securities
Litigation Reform Act of 1995 and other laws and regulations. Forward-looking
statements speak only as to the date made, and may be identified by the use of
forward-looking terms such as "may," "will," "expects," "believes,"
"anticipates," "plans," "estimates," "projects," "targets," "forecasts,"
"outlook," "impact," "potential," "confidence," "improve," "optimistic,"
"deliver," "comfortable," "trend", and "seeks," or the negative of such terms
or other variations on such terms or comparable terminology. Many important
factors could cause actual results to differ materially from those in the
forward-looking statements including, without limitation, disruption of
production or supplies, changes in market conditions, political events,
pending or future claims or litigation, competitive factors, technology
advances, actions of regulatory agencies, and changes in laws, government
regulations, labeling or product approvals or the application or
interpretation thereof. Other risk factors are described herein and in the
Company's Form 10-K and other securities filings. Many of these important
factors are outside STERIS's control. No assurances can be provided as to any
result or the timing of any outcome regarding matters described in the
referenced press release or conference call or otherwise with respect to any
regulatory action, administrative proceedings, government investigations,
litigation, warning letters, consent decree, rebate program, transition, cost
reductions, business strategies, earnings or revenue trends or future
financial results (including without limitation the settlement of the SYSTEM 1
class action litigation and the regulatory matters related to SYSTEM 1E or its
accessories). References to products, the consent decree, the transition or
rebate program, or the class action settlement, are summaries only and should
not be considered the specific terms of the decree, settlement, program or
product clearance or literature. Unless legally required, the Company does not
undertake to update or revise any forward-looking statements even if events
make clear that any projected results, express or implied, will not be
realized. Other potential risks and uncertainties that could cause actual
results to differ materially from those in the forward-looking statements
include, without limitation, (a)the potential for increased pressure on
pricing or costs that leads to erosion of profit margins, (b)the possibility
that market demand will not develop for new technologies, products or
applications or the Company's rebate program, transition plan or other
business initiatives will take longer, cost more or produce lower benefits
than anticipated, (c)the possibility that application of or compliance with
laws, court rulings, certifications, regulations, regulatory actions,
including without limitation those relating to FDA warning notices or letters,
government investigations, the April20, 2010 consent decree and related
transition plan and rebate program, the SYSTEM 1E device, the outcome of any
pending FDA requests, inspections or submissions, or other requirements or
standards may delay, limit or prevent new product introductions, affect the
production and marketing of existing products or services or otherwise affect
Company performance, results, prospects or value, (d)the potential of
international unrest, economic downturn or effects of currencies, tax
assessments, adjustments, or anticipated rates, raw material costs or
availability, benefit or retirement plan costs, or other regulatory compliance
costs, (e)the possibility of reduced demand, or reductions in the rate of
growth in demand, for the Company's products and services, (f)the possibility
that anticipated growth, cost savings, rebate assumptions, new product
acceptance, performance or approvals, including without limitation SYSTEM 1E
and accessories thereto, or other results may not be achieved, or that
transition, labor, competition, timing, execution, regulatory, governmental,
or other issues or risks associated with our business, industry or initiatives
including, without limitation, the consent decree, rebate program, and the
transition from the SYSTEM 1 processing system and adjustments to related
reserves, or those matters described in our Form 10-K for the year ended
March31, 2012 and other securities filings, may adversely impact company
performance, results, prospects or value, (g)the possibility that anticipated
financial results or benefits of recent acquisitions will not be realized or
will be other than anticipated, (h) the effect of the contraction in credit
availability, as well as the ability of our Customers and suppliers to
adequately access the credit markets when needed, and (i)those risks
described in our securities filings including our Annual Report on Form 10-K
for the year ended March31, 2012, and other securities filings.

Contact: Julie Winter, Director, Investor Relations at 440-392-7245.


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Steris Corporation via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.